Endometrial Cancer

>

Latest News

gynecologic system
Postsurgical Pembrolizumab/Chemotherapy Misses DFS Goal in Endometrial Cancer

September 15th 2024

While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.

Oncology Drugs Approved by the FDA in August 2024
Oncology Drugs Approved by the FDA in August 2024

September 3rd 2024

FDA Expands Approval of Dostarlimab for Advanced, Recurrent Endometrial Cancer
FDA Expands Approval of Dostarlimab for Advanced, Recurrent Endometrial Cancer

August 1st 2024

Dostarlimab Plus Chemo Exhibits Overall Survival Benefit in Endometrial Cancer Regardless of MMR Status
Dostarlimab Plus Chemo Exhibits Overall Survival Benefit in Endometrial Cancer Regardless of MMR Status

July 26th 2024

Durvalumab-Based Regimen Improves Overall Response Rate in Endometrial Cancer
Durvalumab-Based Regimen Improves Overall Response Rate in Endometrial Cancer

July 2nd 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.